CTRV News Alert Contravir Pharmaceut (CTRV) 2.1100 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Contravir Pharmaceut (CTRV) 2.1100 $CTRV

Chimerix and ContraVir team up in antiviral development
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 9:23AM CST

CMRX: 36.80 (+0.70), GILD: 91.29 (+1.84)

Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 3.08 (+0.12), CMRX: 36.80 (+0.70)

ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 3.08 (+0.12)

ContraVir Pharmaceuticals' CEO Issues Letter to Shareholders Highlighting Significant Progress
PR Newswire - Thu Dec 11, 9:10AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that its Chief Executive Officer James Sapirstein issued a letter to shareholders highlighting the significant progress the company has made toward its vision of becoming a leading developer of targeted antiviral therapies.
SGYP: 3.08 (+0.12)

ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Tue Dec 09, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has initiated a pharmacokinetic (PK) study of FV-100, the Company's clinical-stage antiviral for treating shingles. The PK study, to be conducted at Duke University in early 2015, is designed to further understand the effect of a potent inhibitor of Cytochrome P450 3A4 on the pharmacokinetics of FV-100, allowing ContraVir to better understand the potential for clinically important drug-drug interactions and to further optimize treatment for Phase 3 development.
SGYP: 3.08 (+0.12)

ContraVir Pharmaceuticals Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Wed Nov 05, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place November 10-13, 2014 at Oxford University in the UK. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment.
SGYP: 3.08 (+0.12)

ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles
PR Newswire - Thu Oct 16, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading contract research organization (CRO), to conduct a Phase 2b clinical trial of ContraVir's lead clinical asset, FV-100, in shingles patients. The planned Phase 2b study is designed to measure the efficacy of FV-100 for treating the severe, lingering nerve pain commonly associated with shingles known as post-herpetic neuralgia (PHN), as well as to optimize the dose and regimen to be used for registration studies.
SGYP: 3.08 (+0.12)

ContraVir Pharmaceuticals raises USD9.0m in private placement of Series A convertible preferred stock
M2 - Thu Oct 16, 5:08AM CDT
Biopharmaceutical company ContraVir Pharmaceuticals (OTC BB :CTRV) revealed on Wednesday the completion of USD9.0m in private placement of Series A convertible preferred stock with a non US investor .

ContraVir Pharma raises capital to fund development of shingles product candidate
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:26PM CDT


ContraVir Pharmaceuticals Closes $9.0 Million Financing to Advance Lead Shingles Candidate
PR Newswire - Wed Oct 15, 5:58AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million. The Preferred Stock is convertible at any time into shares of common stock at a conversion price of $0.48 per share. The investor has agreed to lock-up the shares of Preferred Stock and the underlying common stock until April 14, 2016.
SGYP: 3.08 (+0.12)

Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors; Expands Board to Five Members
GlobeNewswire - Thu Sep 04, 4:29PM CDT
Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company" , a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression as well as obstructive, central and mixed sleep apnea, announces that James E. Sapirstein and Kathryn MacFarlane have joined the Board of Directors of the Company as independent directors. Both have distinguished careers in the biopharmaceutical industry and bring a depth and variety of professional experiences to the Cortex Board of Directors.
BMY: 59.15 (-0.01), TBRA: ()

ContraVir to Present at Two Upcoming Investor Conferences
PR Newswire - Wed Sep 03, 3:42PM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today it will present at two upcoming investor conferences. ContraVir is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, to be held September 8-10, 2014, in New York City, and the Aegis Capital 2014 Healthcare and Technology Conference, to be held September 10-13, 2014 in Las Vegas.
SGYP: 3.08 (+0.12)

ContraVir Appoints Industry Veteran William Hornung as Its Chief Financial Officer
Business Wire - Tue Jul 08, 5:00AM CDT
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), an emerging biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that William Hornung has joined the Company as its Chief Financial Officer. Mr. Hornung has over 22 years of finance and operations leadership experience in the biopharmaceutical industry with companies such as PTC Therapeutics (NASDAQ TCT), Elan Pharmaceuticals, and The Liposome Company.
SGYP: 3.08 (+0.12), PTCT: 51.66 (+0.76)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 6

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 40

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 41

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
Worker Pullback Is a Cost Problem Employers Ignore

Updated Category News Views 31

Somewhere between a job description and an unpaid favor, a lot of corporate productivity appears to be quietly leaking out. MyPerfectResume’s July 2026 survey of 1,000 U.S. workers says 78% have intentionally done only the minimum needed to keep their jobs at least once. That is not a cute workplace-culture headline. It is a warning flare about discretionary...

Continue Reading
Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 6

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 49

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 95

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 43

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading

Top 5 Most Recently Viewed Articles

America Movil Reports Impressive Earnings Boosting Shares

Updated Category News Views 61

America Movil's Earnings Release Raises Investor Confidence America Movil (NYSE: AMX) has recently experienced a notable increase in its shares, rising by 1.4%. This uptick followed the announcement of the company's Q3 2024 earnings, which reported impressive growth in EBITDA. Analysts from Citi attributed this success to robust operations across key markets and favorable...

Continue Reading
QuEra Advances to Stage B of DARPA's Quantum Initiative

Updated Category News Views 204

QuEra's Groundbreaking Leap in Quantum Computing Following a successful Phase A, QuEra is set to advance its quantum technology with substantial funding from DARPA aimed at utility-scale neutral-atom quantum computing. This funding will bolster QuEra's Stage B research and development plan, steering the path toward greater capabilities in quantum computing technology....

Continue Reading
Understanding the Trends in Marriott International's Options Trading

Updated Category News Views 219

Insights on Options Trading for Marriott International Financial giants have recently showcased a notable bullish sentiment towards Marriott International (NASDAQ: MAR). Our investigation into the historical options trading of Marriott reveals some intriguing patterns and trades that signal potential price movements. The Bullish and Bearish Landscape Our breakdown of the...

Continue Reading
Thanksgiving Celebrations: Community, Cannabis, and Kindness

Updated Category News Views 196

Thanksgiving Celebrations: Community, Cannabis, and Kindness This Thanksgiving, a remarkable event unfolded in Flint, Michigan, where Light'N Up Cannabis Company took to the streets with an inspiring mission: to donate 1,000 turkeys to families in need. This heartwarming giveaway, which occurred on a Saturday, reflects the company's commitment to the community. Founded by...

Continue Reading
Flashnet Expands Smart Street Lighting Operations in the USA

Updated Category News Views 317

Flashnet Expands Smart Street Lighting Operations Flashnet, a prominent player in the global smart street lighting sector, is thrilled to announce the expansion of its operations in the United States with the launch of Flashnet LLC. This strategic move is aimed at fortifying the company's commitment to delivering tailored expertise and effective support to municipalities,...

Continue Reading